TITLE

The winds of regulatory change are coming to dental marketing

AUTHOR(S)
Caiafa, Mike
PUB. DATE
November 2009
SOURCE
Proofs;Nov2009, Vol. 92 Issue 5, p66
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article considers the inevitability of change in dental marketing. Identified reasons behind the changes include professional dental associations, the U.S. Food and Drug Administration, state governments and related associations. It describes hypothetical scenarios as illustration of change in dental marketing. Tips to address these changes include establishing in-house regulatory and compliance team and paying close attention to potential legislation activities at the state and federal levels, among others.
ACCESSION #
45152682

 

Related Articles

  • Food and Drug Administration: Reclassification of Blade Form Dental Implants. Hughes, E. Richard // Journal of Oral Implantology;Oct2013, Vol. 39 Issue 5, p523 

    The author describes his testimony with Doctor Ralph Roberts before the U.S. Food and Drug Administration's (FDA) Dental Products Panel of the Medica Devices Committee regarding the reclassification of blade form endosseous dental implants. He asserts that the reclassification of such implant...

  • Blade-Form Dental Implants: FDA Reclassification as a Class II Dental Implant Device. Rutkowski, James L. // Journal of Oral Implantology;Dec2013, Vol. 39 Issue 6, p633 

    The author comments on the plan of the U.S. Food and Drug Administration (FDA) to reclassify blade-form endosseous dental implants from a Class III device to a Class II device. The Class III regulatory pathway consists of extensive preclinical studies and clinical trials and requires premarket...

  • FDA Weighing A New Labeling System for Medical and Dental Products in the U.S. Freedman, Fred // Proofs;Jan2007, Vol. 90 Issue 1, p95 

    The article offers information on the Unique Device Identification program of the U.S. Food and Drug Administration. Most or all dental products, including dental software, for the U.S. market is included in the program and affects nearly all manufacturers, laboratories and distributors. In the...

  • FDA Drug Approvals.  // Formulary;Jan2001, Vol. 36 Issue 1, p9 

    Introduces drugs approved by the United States Food and Drug Administration (FDA). Use of Azelastine HCL in treating symptoms of vasomotor rhinitis; Application of Enoxaparin sodium for prophylaxis of deep vein thrombosis; Efficacy of Neurontin, an antiepileptic drug.

  • Vitamin leaders sit out fight. DeNitto, Emily // Advertising Age;1/3/1994, Vol. 65 Issue 1, p32 

    Reports on efforts of vitamin supplements groups to extend the compliance date on the moratorium on vitamins, minerals and herbs marketing imposed by the Food and Drug Administration. Legislation introduced by Senator Orrin Hatch and Representative Bill Richardson; Public service announcements...

  • FDA Warns Online Pharmacies.  // Pharmaceutical Representative;Jan2010, Vol. 40 Issue 1, p11 

    The article reports on the issuance of letters by the Food and Drug Administration (FDA) to operators of online pharmacies to warn them against illegal drug sales online in the U.S.

  • FDA dispenses advice on patient testimonials. Dickinson, James G. // Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p14 

    The article reports on the advice given by the U.S. Food and Drug Administration (FDA) to drug marketers on how to incorporate patient testimonials and case studies into their advertising and promotion.

  • FDA cites Sanofi-Synthelabo on Plavix promo.  // Medical Marketing & Media;Jul2001, Vol. 36 Issue 7, p32 

    Focuses on the comments of the U.S. Food and Drug Administration over the use of visual sales aid for the marketing of anti-platelet drug Plavix by Sanofi-Synthelabo company.

  • FDA Actions.  // Clinical Cardiology Alert;Mar2010 Supplement 2, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the marketing of diabetes drug, liraglutide under the trade name of Victoza, in March 2010.

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics